Compare AGPU & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | SNOA |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.1M |
| IPO Year | N/A | 2006 |
| Metric | AGPU | SNOA |
|---|---|---|
| Price | $1.88 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.7K | 11.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,288,000.00 |
| Revenue This Year | $486.27 | $23.00 |
| Revenue Next Year | $65.50 | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $2.00 | $1.77 |
| 52 Week High | $9.00 | $6.92 |
| Indicator | AGPU | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 41.38 |
| Support Level | N/A | $2.80 |
| Resistance Level | $2.51 | $3.85 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 1.66 | 50.02 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.